Regeneron price target raised to $1,135 from $1,045 at Truist

Truist raised the firm’s price target on Regeneron to $1,135 from $1,045 and keeps a Buy rating on the shares. The firm is updating its model following the company’s Q4 results, citing Eylea HD traction across all patients as well as Dupixent performance that continues to drive growth through expansion, the analyst tells investors in a research note. Truist expects 2024 to be a “catalyst rich year” for Regeneron, noting its “underappreciated pipeline” setting the stock up for growth.